Jun 1, 2025, 12:54

Mechanistic Links between Diet, Lipid Metabolism, and Tumor Growth and Progression (UH2 Clinical Trial Not Allowed)

This UH2 exploratory/developmental cooperative agreement supports fundamental mechanistic studies that define how dietary variables influence lipid metabolism to drive tumor growth and progression. Projects should bridge nutrition science and molecular metabolism, elucidating how specific diets or macronutrient manipulations alter lipid pathways in tumor cells or the tumor microenvironment. Applicants may include limited unpublished preliminary data (one figure, half page) to welcome new investigators.

Eligibility Criteria

Applicant Types: U.S.-based higher education institutions (public or private), nonprofits (with or without 501(c)(3) status), for-profit organizations (including small businesses), local/state/tribal governments, and federal agencies. Foreign organizations are not eligible; foreign components of U.S. organizations are allowed.
PD/PI Qualifications: Must have expertise in both cancer research and nutrition science; inclusion of a co-investigator or use of an MPI structure with formal training in nutrition is strongly encouraged.
Application Types Allowed: New and Resubmission.
Clinical Trial: Not allowed.
Preliminary Data: Limited to one unpublished figure (½ page). Applications with more than one figure or exceeding half a page of unpublished data will be deemed noncompliant.
Registrations: Applicant organization must maintain active SAM.gov, eRA Commons, and Grants.gov registrations. All PD(s)/PI(s) must have an eRA Commons account by time of submission.

Funding Details

Mechanism: UH2 Exploratory/Developmental Cooperative Agreement Phase I.
Budget: Up to $275,000 total direct costs over two years (no more than $200,000 direct costs in any single year).
Project Period: Maximum of two years.
Number of Awards: Dependent on NCI appropriations and the volume of meritorious applications.
NIH Policy Compliance: Must adhere to NIH Data Management and Sharing, Genomic Data Sharing, and all relevant NIH policies.

Deadline

First Available Due Date: February 14, 2025 (for New and Resubmission).
Second Cycle Due Date: October 23, 2025 (for New and Resubmission).
Letter of Intent (Optional): 30 days before each due date.
Expiration Date: October 24, 2025.
All applications are due by 5:00 PM local time of the applicant organization. Late submissions will not be accepted.

Where to Go for Further Information

Full Announcement: Search PAR-25-118 on Grants.gov or the NIH Guide for Grants and Contracts.
Scientific Inquiries (Tumor Cell Autonomous):

Kristine Willis, Ph.D.

Tel: 301-792-1338

Email: [email protected]
Scientific Inquiries (Tumor Cell Non-Autonomous):

Natalia Mercer, Ph.D.

Tel: 240-276-6220

Email: [email protected]
Peer Review Contact:

Referral Officer, NCI

Tel: 240-276-6390

Email: [email protected]
Grants Management Contact:

Amy Bartosch

Tel: 240-276-6375

Email: [email protected]